CannabisCannTeenANCT04851392
Do Adolescents and Adults Differ in Their Acute Response to Cannabis?
A study testing Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and Cannabis with THC without CBD in people with Cannabis and Cannabis Intoxication, run by University College, London at 1 site in United Kingdom.
Trial summary
The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural… Read more about this study
- Who is it for?
- Ages 16 to 29 yearsHealthy volunteers can take part
- Conditions the study is for
- Cannabis, Cannabis Intoxication, Cannabis Use
- What is being tested?
- Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and Cannabis with THC without CBD
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 11 Mar 2019to 16 Jun 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 29 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Adolescents: Aged 16-17
- Adults: Aged 26-29 years
- Self-reported cannabis use between 0.5 and 3 days/week, averaged over the last 3 months
- Adults: Body mass index (BMI) between 18.5 and 29.9
- Adolescents: BMI between 2nd percentile and 98th percentile
- Self-reported ability to consume approximately half a typical joint of cannabis by themselves within 20 minutes
- Willing to be cannulated and have four blood samples taken at every acute session
- Right-handed
Who cannot join
- Females: Pregnant or breast-feeding
- Adults: Before the age of 18, had a period of 3 or more months when cannabis was used once per week or more frequently.
- Severe cannabis use disorder (DSM-5)
- Illicit drug use of any specific drug more than twice per month, averaged over the last 3 months
- Receiving treatment (pharmacological or psychological) for a mental health problem within the last month
- Lifetime psychosis
Show all 18Show fewer
- Lifetime psychosis of any immediate family member
- Hypertension (systolic > 160 or diastolic > 100)
- Dependent on tobacco or vaping nicotine (> 1 on the Heaviness of Smoking Index)
- Currently taking a psychotropic medication that will likely affect dependent variables or interact with cannabis
- Any physical or mental health condition, any medication, or any treatment, that the study doctor considers to be an exclusion
- MRI contraindications
- Significant asthma or respiratory problems - severity judged clinically
- Self-reported moderate/severe acute unpleasant effects from cannabis which occur often or always
- Positive alcohol breathalyser reading at any acute session (rearrange session)
- Self-reported use of alcohol within 24 hours at any acute session (rearrange session)
- Self-reported use of illicit drugs (including cannabis) within 72 hours at any acute session (rearrange session)
- Positive saliva drug screen at any acute session (rearrange session)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?
The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).
- Conditions
- Cannabis, Cannabis Intoxication, Cannabis Use, Cannabis Dependence, Marijuana, THC
- Being tested
- Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), Cannabis with THC without CBD, Placebo cannabis
- Keywords
- Cannabis, Marijuana, THC, CBD, Adolescence, fMRI, Cognition, Subjective effects, Psychotomimetic effects
- Medical subject headings
- Marijuana Abuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)Drug
Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
Cannabis with THC without CBDDrug
Cannabis with THC without CBD - inhaled and vaporised cannabis flower
Placebo cannabisDrug
Placebo cannabis, without THC and without CBD - inhaled and vaporised
| Study group | Role | What they receive |
|---|---|---|
| THC condition | Experimental | THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC. A 75kg person receives 8mg of THC.
Route of administration: vaporised and inhaled.
Frequency: once.
Duration: inhaled in < 18 minutes. Receives: Drug: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) |
| THC+CBD condition | Experimental | THC+CBD condition: Cannabis with THC and CBD (i.e. THC+CBD condition). 0.107mg/kg of THC and 0.320mg/kg of CBD. A 75kg person receives 8mg of THC and 24mg of CBD.
Route of administration: vaporised and inhaled.
Frequency: once.
Duration: inhaled in < 18 minutes. Receives: Drug: Cannabis with THC without CBD |
| PLA condition | Placebo comparator | PLA condition: Placebo cannabis with no THC or CBD.
Route of administration: vaporised and inhaled.
Frequency: once.
Duration: inhaled in < 18 minutes. Receives: Drug: Placebo cannabis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Psychotomimetic effect
Measured by total Psychotomimetic States Inventory (PSI) score
Measured: Measured once, 2 hours after the start of drug administration, on each drug condition
Verbal episodic memory
Measured by delayed prose recall performance
Measured: Measured once, 2 hours after the start of drug administration, on each drug condition
Strength of subjective drug effect
Measured by self-reported 'feel drug effect', rated from 0 (not at all) to 10 (extremely)
Measured: Measured 20 minutes after the start of drug administration, on each drug condition
Secondary outcomes (11)
Self-reported subjective effects
Feel drug effect, like drug effect, dislike drug effect, alert, want to have cannabis, happy, relaxed, anxious, paranoid, mentally impaired, stoned, dry mouth, unmotivated, intensified sensory perception, want to listen to music, want food, want to see friends, rated from 0 (not at all) to 10 (extremely)
Measured: Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Functional magnetic resonance imaging (fMRI) measured neural correlates
Reward anticipation and reward feedback, response inhibition, spatial working memory, and resting-state
Measured: Measured between 40 minutes and 1 hour & 20 minutes after the start of drug administration, on each drug condition
Magnetic resonance spectroscopy
Measuring glutamate levels in the dorsal striatum
Measured: Measured 1 hour & 30 minutes after the start of drug administration, on each drug condition
Positive and negative syndrome scale
Kay et al. (1987). Higher scores reflect stronger positive and negative symptoms.
Measured: Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition
Effort-related decision-making (i.e. amotivation)
Measured by the physical effort task ('apple-gathering' task) as described in Husain \& Roiser (2018)
Measured: Measured 2 hours & 20 minutes after the start of drug administration, on each drug condition
Pleasure processing
Measured by subjective liking in response to chocolate, music and cartoons, rated from 0 (not at all) to 10 (extremely), similar to Lawn et al. (2015)
Measured: Measured 2 hours & 30 minutes after the start of drug administration, on each drug condition
Visual attentional bias to cannabis and food stimuli
Measured by the visual dot-probe task, as described in Morgan et al. (2010)
Measured: Measured 2 hours & 10 minutes after the start of drug administration, on each drug condition
Heart rate
Measuring heart rate
Measured: Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Blood pressure
Measuring systolic and diastolic blood pressure.
Measured: Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Exogenous and endogenous cannabinoid levels in plasma
Measuring THC and CBD and metabolites; and endocannabinoids
Measured: Measured -30 minutes, 20 minutes, 30 minutes, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Dissociative states scale
Bremner et al. (1998). Higher scores reflect greater dissociation.
Measured: Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2021
- Study start11 Mar 2019
- Primary completion16 Jun 2021
- Study completion16 Jun 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for CannabisStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Double-blind, placebo-controlled, crossover experiment with drug condition block randomised and stratified by age-group and gender, such that drug order is counterbalanced. There are two groups: adolescents (16-17 years old) and adults (26-29 years old). These groups are matched on current cannabis use frequency. There are three drug conditions: (1) cannabis with delta-9-tetrahydrocannabinol (THC) and without cannabidiol (CBD), (2) cannabis with THC but without CBD, and (3) placebo cannabis without THC and without CBD.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Collaborators
- Medical Research Council, Invicro
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04851392
- Sponsor's protocol ID
- 5929/005
- Acronym
- CannTeenA
- Status last verified
- Sep 2021
- First submitted
- 5 Apr 2021
- Last updated
- 29 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hall D, Lawn W, Ofori S, Trinci K, Borissova A, Mokrysz C, Petrilli K, Bloomfield MAP, Wall MB, Freeman TP, Curran HV. The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study. Psychopharmacology (Berl). 2024 Jun;241(6):1125-1134. doi: 10.1007/s00213-024-06543-7. Epub 2024 Feb 28.
PubMed 38416223Lawn W, Trinci K, Mokrysz C, Borissova A, Ofori S, Petrilli K, Bloomfield M, Haniff ZR, Hall D, Fernandez-Vinson N, Wang S, Englund A, Chesney E, Wall MB, Freeman TP, Curran HV. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment. Addiction. 2023 Jul;118(7):1282-1294. doi: 10.1111/add.16154. Epub 2023 Feb 26.
PubMed 36750134Skumlien M, Freeman TP, Hall D, Mokrysz C, Wall MB, Ofori S, Petrilli K, Trinci K, Borissova A, Fernandez-Vinson N, Langley C, Sahakian BJ, Curran HV, Lawn W. The Effects of Acute Cannabis With and Without Cannabidiol on Neural Reward Anticipation in Adults and Adolescents. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Feb;8(2):219-229. doi: 10.1016/j.bpsc.2022.10.004. Epub 2022 Oct 28.
PubMed 36642667Dhami P, Quilty LC, Schwartzmann B, Uher R, Allen TA, Kloiber S, Lam RW, MacQueen G, Frey BN, Milev R, Muller DJ, Strother SC, Blier P, Soares CN, Parikh SV, Turecki G, Foster JA, Rotzinger S, Kennedy SH, Farzan F. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Feb;8(2):162-170. doi: 10.1016/j.bpsc.2021.12.012. Epub 2022 Jan 13.
PubMed 35032682
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?
- ClinicalTrials.gov ID
- NCT04851392
- Acronym / sponsor ID
- CannTeenA / 5929/005
- Conditions
- Cannabis, Cannabis Intoxication, Cannabis Use, Cannabis Dependence, Marijuana, THC
- Keywords
- Cannabis, Marijuana, THC, CBD, Adolescence, fMRI, Cognition, Subjective effects
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Collaborators
- Medical Research Council, Invicro
- Study start
- 11 Mar 2019 (actual)
- Primary completion
- 16 Jun 2021 (actual)
- Study completion
- 16 Jun 2021 (actual)
- First posted
- 20 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
- Model description
- Double-blind, placebo-controlled, crossover experiment with drug condition block randomised and stratified by age-group and gender, such that drug order is counterbalanced. There are two groups: adolescents (16-17 years old) and adults (26-29 years old). These groups are matched on current cannabis use frequency. There are three drug conditions: (1) cannabis with delta-9-tetrahydrocannabinol (THC) and without cannabidiol (CBD), (2) cannabis with THC but without CBD, and (3) placebo cannabis without THC and without CBD.
| Arm | Type | Receives |
|---|---|---|
| THC condition | Experimental | Drug: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC. A 75kg person receives 8mg of THC. Route of administration: vaporised and inhaled. Frequency: once. Duration: inhaled in < 18 minutes. |
| THC+CBD condition | Experimental | Drug: Cannabis with THC without CBDTHC+CBD condition: Cannabis with THC and CBD (i.e. THC+CBD condition). 0.107mg/kg of THC and 0.320mg/kg of CBD. A 75kg person receives 8mg of THC and 24mg of CBD. Route of administration: vaporised and inhaled. Frequency: once. Duration: inhaled in < 18 minutes. |
| PLA condition | Placebo comparator | Drug: Placebo cannabisPLA condition: Placebo cannabis with no THC or CBD. Route of administration: vaporised and inhaled. Frequency: once. Duration: inhaled in < 18 minutes. |
Who may qualify
- Ages
- 16 to 29 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (8 listed)
- Adolescents: Aged 16-17
- Adults: Aged 26-29 years
- Self-reported cannabis use between 0.5 and 3 days/week, averaged over the last 3 months
- Adults: Body mass index (BMI) between 18.5 and 29.9
- Adolescents: BMI between 2nd percentile and 98th percentile
Key exclusion criteria (18 listed)
- Females: Pregnant or breast-feeding
- Adults: Before the age of 18, had a period of 3 or more months when cannabis was used once per week or more frequently.
- Severe cannabis use disorder (DSM-5)
- Illicit drug use of any specific drug more than twice per month, averaged over the last 3 months
- Receiving treatment (pharmacological or psychological) for a mental health problem within the last month
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower | Drug | THC condition |
| Cannabis with THC without CBDCannabis with THC without CBD - inhaled and vaporised cannabis flower | Drug | THC+CBD condition |
| Placebo cannabisPlacebo cannabis, without THC and without CBD - inhaled and vaporised | Drug | PLA condition |
Primary outcome
Psychotomimetic effect
Time frame: Measured once, 2 hours after the start of drug administration, on each drug condition
Measured by total Psychotomimetic States Inventory (PSI) score
Verbal episodic memory
Time frame: Measured once, 2 hours after the start of drug administration, on each drug condition
Measured by delayed prose recall performance
Strength of subjective drug effect
Time frame: Measured 20 minutes after the start of drug administration, on each drug condition
Measured by self-reported 'feel drug effect', rated from 0 (not at all) to 10 (extremely)
11 secondary outcomes
Self-reported subjective effects
Time frame: Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Functional magnetic resonance imaging (fMRI) measured neural correlates
Time frame: Measured between 40 minutes and 1 hour & 20 minutes after the start of drug administration, on each drug condition
Magnetic resonance spectroscopy
Time frame: Measured 1 hour & 30 minutes after the start of drug administration, on each drug condition
Positive and negative syndrome scale
Time frame: Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition
Effort-related decision-making (i.e. amotivation)
Time frame: Measured 2 hours & 20 minutes after the start of drug administration, on each drug condition
Pleasure processing
Time frame: Measured 2 hours & 30 minutes after the start of drug administration, on each drug condition
Visual attentional bias to cannabis and food stimuli
Time frame: Measured 2 hours & 10 minutes after the start of drug administration, on each drug condition
Heart rate
Time frame: Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Blood pressure
Time frame: Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Exogenous and endogenous cannabinoid levels in plasma
Time frame: Measured -30 minutes, 20 minutes, 30 minutes, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Dissociative states scale
Time frame: Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2021.
- Derived from this study: PubMed 38416223Hall D, Lawn W, Ofori S, Trinci K, Borissova A, Mokrysz C, Petrilli K, Bloomfield MAP, Wall MB, Freeman TP, Curran HV. The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study. Psychopharmacology (Berl). 2024 Jun;241(6):1125-1134. doi: 10.1007/s00213-024-06543-7. Epub 2024 Feb 28.
- Derived from this study: PubMed 36750134Lawn W, Trinci K, Mokrysz C, Borissova A, Ofori S, Petrilli K, Bloomfield M, Haniff ZR, Hall D, Fernandez-Vinson N, Wang S, Englund A, Chesney E, Wall MB, Freeman TP, Curran HV. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment. Addiction. 2023 Jul;118(7):1282-1294. doi: 10.1111/add.16154. Epub 2023 Feb 26.
- Derived from this study: PubMed 36642667Skumlien M, Freeman TP, Hall D, Mokrysz C, Wall MB, Ofori S, Petrilli K, Trinci K, Borissova A, Fernandez-Vinson N, Langley C, Sahakian BJ, Curran HV, Lawn W. The Effects of Acute Cannabis With and Without Cannabidiol on Neural Reward Anticipation in Adults and Adolescents. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Feb;8(2):219-229. doi: 10.1016/j.bpsc.2022.10.004. Epub 2022 Oct 28.
- Derived from this study: PubMed 35032682Dhami P, Quilty LC, Schwartzmann B, Uher R, Allen TA, Kloiber S, Lam RW, MacQueen G, Frey BN, Milev R, Muller DJ, Strother SC, Blier P, Soares CN, Parikh SV, Turecki G, Foster JA, Rotzinger S, Kennedy SH, Farzan F. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Feb;8(2):162-170. doi: 10.1016/j.bpsc.2021.12.012. Epub 2022 Jan 13.
- Individual participant dataSharing planned: No
Related trials for Cannabis
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
RecruitingPhase 3
Nabilone for Agitation Blinded Intervention Trial
Alzheimer Disease, Agitation
Not yet recruitingPhase 1
PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis
Cigarette Smoking-Related Carcinoma
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and Cannabis with THC without CBD in people with Cannabis and Cannabis Intoxication, run by University College, London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Psychotomimetic effect (time frame: Measured once, 2 hours after the start of drug administration, on each drug condition). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04851392, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2021.